Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986253 with Nivolumab and Ipilimumab in Advanced Cancers
NCT03400332Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of adakitug in cancer, melanoma, sponsored by Bristol Myers Squibb. Started Feb 2018; status: completed.
02
Drugs
adakitug
03
Conditions
cancermelanoma
Beyond the preview
Go deeper on NCT03400332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400332.